NuScale Power (NYSE: SMR) stock is trading at $7.18, having shed nearly half its value year-to-date, forcing shareholders to weigh whether the battered shares represent dead money or a genuine recovery opportunity.
The broader market has moved in the opposite direction, with the SPDR S&P 500 ETF Trust (NYSEARCA: SPY) posting a 14% gain year-to-date, making NuScale’s underperformance especially stark by comparison.
The small modular reactor sector has broadly struggled, with rival developer Oklo (NYSE: OKLO) falling 52% year-to-date to trade at $34.65, a slightly steeper decline than NuScale has experienced through the same period.
Centrus Energy (NYSEAMERICAN: LEU), which differs from both developers in that it actively enriches uranium and sells fuel today, has declined 41% year-to-date to trade at $143.98, a smaller loss but still a painful one.
The Global X Uranium ETF (NYSEARCA: URA) has held up comparatively well, declining only 9% year-to-date, and the gap between that fund and the two pre-revenue developers sits at the center of the dead-money debate.
NuScale reported quarterly revenue of just $75,000 in August, a dramatic collapse from the prior-year period, following the completion of front-end engineering work that had previously generated its billable scope.
In that same month, NuScale filed to sell an additional $750 million in shares through an at-the-market offering, layered on top of equity the company had already issued during the first half of the year.
NuScale does not expect to deploy its small modular reactor technology commercially until the early part of the next decade, meaning the company must fund years of development through share issuance rather than product sales.
Optimists could argue that the revenue shortfall reflects contract timing rather than structural failure, and that with shares already down 49%, much of the risk associated with a long development runway may already be reflected in the price.
Skeptics counter that an open share-issuance program running alongside a multi-year absence of commercial revenue means shareholders absorb dilution for an extended period before any actual reactor generates a dollar in product revenue.
Shareholders looking for positive signals could monitor whether NuScale secures new engineering, licensing, or consulting contracts to rebuild its revenue line, and track how much of the $750 million at-the-market program has been deployed.
Any narrowing of the performance gap between the uranium ETF and the two pre-revenue developers could also signal that the broader category is attracting renewed investor interest, offering a leading indicator worth watching closely.
Given the persistent dilution risk tied to NuScale’s funding model, analysts suggest keeping position sizes modest enough that additional share issuance does not impose undue strain on a broader investment portfolio.
